Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Generi generi alimentari per i residenti di Southeastern USA per fermare l'ipertensione (GoFreshSE)

14 novembre 2026 aggiornato da: Stephen Juraschek, Beth Israel Deaconess Medical Center

GoFreshSE is a randomized control trial, testing the effects of a home-delivered, dietitian-assisted, DASH-patterned grocery intervention on blood pressure in adults with high blood pressure in Florida, Georgia, and Tennessee.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Hypertension (HTN) affects half of US adults and is one of the most important modifiable risk factors for cardiovascular disease (CVD) and death.

The DASH diet is a proven strategy for lowering blood pressure in adults. Our proposed clinical trial will evaluate the effectiveness of a scalable solution: home-delivered, low-sodium groceries aligned with the DASH dietary pattern and ordered with dietitian assistance via a virtual supermarket, in reducing blood pressure.

Participants will be assigned to one of two 1-month long interventions: (1) dietitian-assisted, DASH-patterned, home-delivered groceries ordered weekly through Amazon Fresh (or Whole Foods) over 4 weeks or (2) self-directed grocery shopping (monthly stipend and DASH diet brochure) (referent).

Tipo di studio

Interventistico

Iscrizione (Stimato)

150

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Beth Israel Deaconess Medical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Resting systolic blood pressure of 120 to <160 mm Hg and diastolic blood pressure <110 mm Hg
  2. Resident of Florida, Georgia, and Tennessee
  3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period
  4. Have access to refrigeration, cooking appliances, and Wi-Fi/cellular service
  5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send/receive text messages
  6. Willing and able to complete required measurement procedures
  7. Able to provide consent for the study
  8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study

Exclusion Criteria:

A. Laboratory Exclusions:

  1. Serum potassium ≥5.4 mmol/L or <3.5 mmol/L
  2. Estimated glomerular filtration rate (eGFR) <30 mL/min per 1.73 m^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  3. Hemoglobin A1c ≥6.5%

B. Medication Exclusions:

Unstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following:

  1. GLP-1 and dual GLP-1/GIP receptor agonists
  2. Anti-hypertension medications
  3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors
  4. Glucose lowering medications

Use of any of the following medications:

  1. Potassium supplement, except if part of a multivitamin
  2. Warfarin (Coumadin)
  3. Chronic oral corticosteroid (intermittent use is okay)
  4. Weight loss medications (non-GLP-1 receptor agonists)
  5. Sulfonylurea or any insulin use

Any medication not compatible with participation as determined by the investigators

C. Physical Exclusions:

  1. Systolic blood pressure: <120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg
  2. Arm circumference >52 cm (or the upper limit of the validated BP device)

D. Medical History Exclusions:

  1. Self-reported weight loss or gain of 15 pounds during prior 2 months
  2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission
  3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)
  4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence
  5. Pregnancy or lactation or planned pregnancy during the study period
  6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months
  7. Hypoglycemia hospitalization in the last 12 months
  8. Any other serious illness or condition not compatible with participation as determined by the investigators

E. Lifestyle and Other Exclusions:

  1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence
  2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week
  3. Active substance use disorder that would interfere with participation
  4. Extreme food insecurity
  5. Participation in or planning to start weight loss program
  6. Current participation in another clinical trial that could interfere with the study protocol
  7. Anticipated change in residence outside of eligible states prior to the end of the study
  8. Families with more than 6 adults at dinner time (children count as half an adult)

F. Investigator discretion

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Dietitian-Assisted DASH Groceries

Participants will order groceries sufficient to meet their caloric needs each week for 4 weeks with the assistance of a dietitian/nutrition interventionist. Groceries will be delivered to participants' homes or picked up at a convenient location. The dietitian/nutrition interventionist will provide brief educational content at the time of food delivery. Orders will be placed via phone or through virtual counseling sessions.

The DASH ("Dietary Approaches to Stop Hypertension"), is a healthy dietary pattern that lowers blood pressure without reducing weight. The DASH diet emphasizes fruits, vegetables, and low-fat dairy products; includes whole grains, poultry, fish, and nuts; and is reduced in red meat, sweets, and sugar-containing beverages.

Intervention Phase:

This intervention is a weekly, 4-week DASH dietary intervention. A dietitian will assist participants in ordering groceries in a pattern consistent with the DASH diet to be delivered to their homes. The quantity of groceries will be based on participant Calorie needs and family size.

Comparatore attivo: Self-directed shopping

Participants will receive a stipend and some basic information about healthy eating. The stipend is not restricted to foods.

Intervention Phase:

Participants will receive some basic information on healthy eating and a stipend during the 4-week intervention period. They are permitted to use the stipend however they choose and will not be asked about how they spent these funds.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Self-measured systolic blood pressure
Lasso di tempo: Measured before and after the 4-week intervention

This entails 4 measurements, 2 in the morning and 2 in the evening, over a 7 day period (at least 3 concurrent days is acceptable for analysis).

Measured before and after the 4-week intervention

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Self-measured diastolic blood pressure
Lasso di tempo: Measured before and after the 4-week intervention

This entails 4 measurements, 2 in the morning and 2 in the evening, over a 7 day period (at least 3 concurrent days is acceptable for analysis).

Measured before and after the 4-week intervention
Seated systolic and diastolic blood pressure (technician-measured)
Lasso di tempo: Measured before and after the 4-week intervention

Seated systolic and diastolic blood pressure measured by a technician in participants' homes, using the office blood pressure device.

Measured before and after the 4-week intervention
Body Mass Index (BMI)
Lasso di tempo: Height is measured before the intervention. Weight is measured before and after the 4-week intervention.

At home measurement based on height and weight measured by a technician via a stadiometer and scale.

Height is measured before the intervention. Weight is measured before and after the 4-week intervention.
24-hour dietary recall
Lasso di tempo: Measured before and after the 4-week intervention

Assessed via self-administered questionnaire using the Automated Self-Administered 24-Hour Dietary Recall (ASA24).

Measured before and after the 4-week intervention
Spot urine sodium/potassium ratio
Lasso di tempo: Measured before and after the 4-week intervention

Measured in urine collected at the participants' homes.

Measured before and after the 4-week intervention
Lipids
Lasso di tempo: Measured before and after the 4-week intervention

Measured in fasted serum specimens collected during phlebotomy. Includes total cholesterol, high density lipoprotein cholesterol, derived low density lipoprotein cholesterol, and triglycerides

Measured before and after the 4-week intervention
Fasting glucose
Lasso di tempo: Measured before and after the 4-week intervention

Measured in blood as part of a basic metabolic panel

Measured before and after the 4-week intervention
Serum potassium
Lasso di tempo: Measured before and after the 4-week intervention

Measured in blood as part of a basic metabolic panel

Measured before and after the 4-week intervention

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
General Health Status
Lasso di tempo: Measured before and after the 4-week intervention

Single General Health Status Question: "Would you say that in general your health is excellent, very good, good, fair, or poor?"

Measured before and after the 4-week intervention
Financial strain
Lasso di tempo: Measured before and after the 4-week intervention

We will ask the following questions: How often does this describe you? I don't have money to pay my bills (including food, housing, medical care or heating).

Never / Rarely / Sometimes / Often / Always

Measured before and after the 4-week intervention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 ottobre 2025

Completamento primario (Stimato)

1 novembre 2026

Completamento dello studio (Stimato)

1 dicembre 2026

Date di iscrizione allo studio

Primo inviato

18 marzo 2025

Primo inviato che soddisfa i criteri di controllo qualità

18 marzo 2025

Primo Inserito (Effettivo)

24 marzo 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • 2025P000102
  • GRT67144 (Altro numero di sovvenzione/finanziamento: American Heart Association)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .